Page 62 - Read Online

Chan et al. Hepatoma Res 2018;4:5 I http://dx.doi.org/10.20517/2394-5079.2017.49 Page 15 of 17

80. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M,
Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for
hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1545-52.
81. Recchia F, Passalacqua G, Filauri P, Doddi M, Boscarato P, Candeloro G, Necozione S, Desideri G, Rea S. Chemoembolization of
unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicineluting beads compared with lipiodol. Oncol Rep
2012;27:1377-83.
82. Gao YJ, He YJ, Yang ZL, Shao HY, Zuo Y, Bai Y, Chen H, Chen XC, Qin FX, Tan S, Wang J, Wang L, Zhang L. Increased integrity of
circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med 2010;48:1651-6.
83. Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN. The treatment responses in cases of radiation therapy to
portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1155-63.
84. Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, Zheng S, Zhou L. Doxorubicin-eluting bead versus conventional TACE for unresectable
hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013;60:813-20.
85. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst
Rev 2011;(3):CD004787.
86. Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G.
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
Hepatology 2010;52:1741-9.
87. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre
GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Inarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A,
Ahmadzadehfar H, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival
after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European
evaluation. Hepatology 2011;54:868-78.
88. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM,
Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J,
Omary RA, Abecassis M, Benson AB 3rd, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity
compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507 e2.
89. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta
R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90
microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64.
90. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90
microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305-14.
91. Kim DY, Park BJ, Kim YH, Han KH, Cho SB, Cho KR, Uhm SH, Choe JG, Choi JY, Chun HJ, Lee HC, Gwon DI, Lee KH, Yoon JH,
Chung JW, Kim CW, Heo J, Kim JK, Joo YE. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a
multicenter prospective study. Am J Clin Oncol 2015;38:495-501.
92. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchiano A, Bongini M, Lanocita R, Civelli E,
Bombardieri E, Camerini T, Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2
study. Hepatology 2013;57:1826-37.
93. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan
Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC,
Roberts LR. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
Cardiovasc Intervent Radiol 2013;36:714-23.
94. El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechene A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF.
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627-35.
95. Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular
carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82.
96. Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, Giacomelli L. Transarterial
radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:25-9.
97. Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of
patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993;27:117-23.
98. Matsuo Y, Yoshida K, Nishimura H, Ejima Y, Miyawaki D, Uezono H, Ishihara T, Mayahara H, Fukumoto T, Ku Y, Yamaguchi M, Sugimoto
K, Sasaki R. Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava
tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy. J Radiat Res 2016;57:512-23.
99. Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for
Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci 2013;28:213-9.
100. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, Ringash J, Dawson LA. Outcomes following definitive stereotactic body
radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-7.
101. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M,
Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J
Clin Oncol 2013;31:1631-9.
102. Lo CH, Yang JF, Liu MY, Jen YM, Lin CS, Chao HL, Huang WY. Survival and prognostic factors for patients with advanced hepatocellular
carcinoma after stereotactic ablative radiotherapy. PLoS One 2017;12:e0177793.
103. Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, Kawanaka K, Beppu T, Sugiyama S, Sakamoto T, Yamashita Y, Oya N.
Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007;84:266-71.